Reagents where the antibody is the analyte: why a centromere antibody, an anti centromere antibody and a crest antibody name a patient autoantibody rather than a reagent you buy antibodies as, what a jo1 antibody, gad antibodies, a 21 hydroxylase antibody, a tshr antibody and an nt5c1a antibody are measured for and why a pattern on a substrate is the classical readout, how a c4d antibody, a c3d antibody, an anti c3 antibody and a c5b-9 antibody detect deposited complement fragments in tissue rather than circulating protein, where a cenpa antibody, a numa antibody, a pericentrin antibody, a coilin antibody, a fibrillarin antibody, an sp100 antibody, a nup98 antibody and an rna polymerase iii antibody are laboratory reagents against the same structures the autoantibodies happen to recognise, and why the two uses must never be described in the same sentence without saying which is meant

Keeping the two uses apart

1. State whether the antibody is reagent or analyte. A reagent detects a target; an autoantibody is the target. Assays, controls and regulatory expectations differ completely, and the same protein name appears in both contexts.
2. Read pattern before titre in autoantibody work. Classical autoantibody testing on a cell substrate reports a staining pattern that suggests a family of specificities, followed by a confirmatory specific assay. The pattern is the screen, not the answer.
3. Detect complement deposition in tissue, not plasma. Deposited fragments in tissue are the informative finding in transplant and immune complex disease. Measuring circulating complement answers a different question about consumption and synthesis.
4. Choose structural reagents for the compartment. Nuclear body, nucleolar, centromere and nuclear pore reagents each give a characteristic pattern that is itself a control. A stain that does not look like the expected structure is a warning.
5. Respect the labelling boundary. Reagents sold for research use may not be used to produce a result that informs clinical care, however capable they are. Where the result will inform care, the assay has to be appropriate to that use.

Same target, two roles

Nuclear and centromeric structures are studied with laboratory reagents and are also the targets of patient autoantibodies, which is not a coincidence: they became known as autoantigens because patient sera stained them.

The overlap makes catalogue searching confusing and the distinction consequential. Say which role you mean, every time.

Patterns are a quality control

Reagents against subnuclear structures produce characteristic, recognisable patterns. That is an unusually good built in control: if the stain does not look like the structure, something is wrong with the reagent or the protocol.

Photograph the expected pattern once on a control sample and keep it with the reagent record.

Common questions

Is a listing for an autoantibody a reagent I can buy?

Sometimes both exist under the same name: a laboratory reagent against the structure, and an assay that measures a patient's antibodies against it. Read the product description carefully, because the two are not interchangeable.

What does a staining pattern tell you?

It narrows the likely specificity to a family and directs which confirmatory assay to run. It is a screening result, and reporting it as a specific diagnosis is not supported.

Why measure deposited complement rather than circulating?

Because deposition in tissue localises the process, which is what matters in transplant rejection and immune complex disease. Circulating levels report consumption and synthesis, which is a different question.

Browse by service class

• Compare Gene synthesis on advertised prices